Study identifier:D5161R00003
ClinicalTrials.gov identifier:NCT03562819
EudraCT identifier:N/A
CTIS identifier:N/A
An observational, multicentre, Prospective study to evaluate concordance of detecting EGFR (Epidermal Growth Factor Receptor) mutation by circulating tumour free DNA versus tissues biopsy in NSCLC (Non-small cell lung cancer).
NSCLC (Non-small cell lung cancer)
N/A
No
-
All
268
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2020 by AstraZeneca
AstraZeneca
-
This is a multicentre, prospective, study of EGFR )Epidermal Growth Factor Receptor) mutation status in advanced NSCLC (Non-small cell lung cancer)patients (locally advanced and/or metastatic disease) with adenocarcinoma histology proposed to be conducted at 15 sites from different geographical regions across India. The study targets to enrol 268 patients over a period of 6 months.
This is a multicentre, prospective, study of EGFR mutation status in advanced NSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma histology proposed to be conducted at 15 sites from different geographical regions across India. The study targets to enrol 268 patients over a period of 6 months. The study will enroll patients with histologically confirmed, systemic treatment naïve adenocarcinoma metastatic cancer (stage IV). This will be a single visit study. No study medication will be prescribed or administered as a part of study procedure.
Location
Location
Kolkata, West Bangal, India, 700160
Location
Kolkata, West Bengal, India, 700054
Location
Mumbai, Maharashtra, India, 400071
Location
Hyderabad, Telanagana, India, 500034
Location
New Delhi, Delhi, India, 110029
Location
Bhubaneswar, Odisha, India, 751007
Location
Bengaluru, Karnataka, India, 560027
Location
New Delhi, Delhi, India, 110085
Arms | Assigned Interventions |
---|---|
NSCLC Non-small cell lung cancer | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.